More specifically, Bill's practice focuses on patent portfolio development to achieve optimum term for pharmaceutical products.  Bill’s clients recently obtained multiple drug product approvals with patent portfolio coverage under development at Mintz. For early stage companies, Bill has assisted in patent portfolio development leading to acquisitions and/or collaborations valued at from about $100M to about $4B. He leverages experience in the corporate setting to provide clients with a business-based, product-driven approach to all of his IP legal services, and includes approaches with potential litigation challenges in mind.  Bill also advises on product protection strategies involving formulations, drug delivery technologies, and dosing methods.

Prior to joining the IP team at Mintz, Bill was a partner in the Bay Area office of a large, international law firm. He also served as in-house patent counsel for Tularik Inc. (now part of Amgen, Inc.), a company involved in the discovery of compounds for the regulation of gene expression.

Earlier, Bill worked as a senior research scientist and project leader for FMC Corporation and Dow Chemical Company/DowElanco, where his research involved the design and synthesis of small molecule regulators of biological processes. Bill's doctoral thesis, conducted under the direction of Professor Paul A. Bartlett at UC Berkeley, concerned the design and synthesis of transition-state analogs as inhibitors of peptidases.